These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 18839649

  • 1. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S, Collier A, Elhadd T, Malik I.
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [Abstract] [Full Text] [Related]

  • 2. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C, Wright A, Chiquette E.
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [Abstract] [Full Text] [Related]

  • 3. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E, Lucotti P, Setola E, Monti L, Piatti PM.
    Diabetes Res Clin Pract; 2008 Dec 15; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [Abstract] [Full Text] [Related]

  • 4. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar 15; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 5. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N, Sriwijitkamol A.
    J Med Assoc Thai; 2008 Jun 15; 91(6):943-54. PubMed ID: 18697398
    [Abstract] [Full Text] [Related]

  • 6. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M.
    Prim Care Diabetes; 2012 Oct 15; 6(3):187-91. PubMed ID: 22613745
    [Abstract] [Full Text] [Related]

  • 7. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B.
    Handb Exp Pharmacol; 2011 Oct 15; (203):53-74. PubMed ID: 21484567
    [Abstract] [Full Text] [Related]

  • 8. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ, McGill MA.
    Clin Drug Investig; 2012 Jan 01; 32(1):1-14. PubMed ID: 21958333
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pathophysiologic role of incretins.
    Freeman JS.
    J Am Osteopath Assoc; 2007 May 01; 107 Suppl():S6-9. PubMed ID: 17724014
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M, Rayfield EJ.
    Mt Sinai J Med; 2009 Jun 01; 76(3):244-56. PubMed ID: 19421968
    [Abstract] [Full Text] [Related]

  • 17. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C, Bollaerts K.
    Int J Clin Pract Suppl; 2007 Aug 01; (154):29-37. PubMed ID: 17593275
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV].
    Perusicová J.
    Vnitr Lek; 2007 Sep 01; 53(9):1005-9. PubMed ID: 18019673
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.